Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's LG Life Sciences Signs Deal With China's Double-Crane Covering DPP-4 Inhibitor Gemigliptin

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes

You may also be interested in...



Korea’s Dong-A Out-licenses DPP-4 To India’s Alkem Laboratories

Staggering under a tightened regulatory grip and price cuts at home, Korea’s Dong-A is trying to capture growth momentum from overseas.

Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?

After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.

Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?

After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel